DPHARMA | DUOPHARMA BIOTECH BHD
1.32 (2.33%)
T-O (am): 0.000 (08:59:00)
T-O (pm): 1.30 (14:29:00)
Last updated: 16:55
Fundamental
Technical
Total Score
DPHARMA Fundamental Trend
FCON: | Sharpe Ratio: | LTS:
DPHARMA Quarter Reports
Customize
Select columns required and click "Update" to save your preferences
| Ann. Date | Qtr. Date | Q | FYE | Revenue [M] | PBT [M] | NP [M] | NPM | DPS | EPS | R. QoQ | R. YoY | E. QoQ | E. YoY | TTM EPS |
Adj. [M] |
NP [M] (adj) |
NPM (adj) |
EPS (adj) |
E. QoQ (adj) |
E. YoY (adj) |
TTM EPS (adj) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 Nov 25 | Q3 Sep 2025 | 3 | 31 Dec 2025 | 222.49 | 29.68 | 22.57 | 10.1% | 0.00 | 2.35 | 0.3% | 6.6% | 11.7% | 44.7% | ||||||||
| 21 Aug 25 | Q2 Jun 2025 | 2 | 31 Dec 2025 | 221.78 | 26.58 | 20.20 | 9.1% | 1.50 | 2.10 | 15.6% | 1.6% | 21.2% | 21.1% | ||||||||
| 15 May 25 | Q1 Mar 2025 | 1 | 31 Dec 2025 | 262.74 | 33.74 | 25.64 | 9.8% | 0.00 | 2.67 | 35.7% | 36.2% | 70.0% | 67.8% | ||||||||
| 19 Feb 25 | Q4 Dec 2024 | 4 | 31 Dec 2024 | 193.67 | 17.44 | 15.08 | 7.8% | 2.00 | 1.57 | 7.2% | 15.6% | 3.3% | 77.4% | ||||||||
| 08 Nov 24 | Q3 Sep 2024 | 3 | 31 Dec 2024 | 208.73 | 20.52 | 15.60 | 7.5% | 0.00 | 1.62 | 4.4% | 23.3% | 6.6% | 73.9% | ||||||||
| 15 Aug 24 | Q2 Jun 2024 | 2 | 31 Dec 2024 | 218.32 | 21.96 | 16.69 | 7.6% | 1.00 | 1.73 | 13.1% | 30.3% | 9.2% | 33.1% | ||||||||
| 23 May 24 | Q1 Mar 2024 | 1 | 31 Dec 2024 | 192.97 | 20.10 | 15.28 | 7.9% | 0.00 | 1.59 | 15.2% | 3.7% | 79.7% | 32.5% | ||||||||
| 22 Feb 24 | Q4 Dec 2023 | 4 | 31 Dec 2023 | 167.50 | 7.03 | 8.50 | 5.1% | 1.80 | 0.88 | 1.0% | 10.2% | 5.2% | 50.5% | ||||||||
| 08 Nov 23 | Q3 Sep 2023 | 3 | 31 Dec 2023 | 169.24 | 11.43 | 8.97 | 5.3% | 0.00 | 0.93 | 1.0% | 4.4% | 28.5% | 45.1% | ||||||||
| 24 Aug 23 | Q2 Jun 2023 | 2 | 31 Dec 2023 | 167.52 | 16.52 | 12.54 | 7.5% | 0.50 | 1.31 | 16.4% | 7.8% | 44.6% | 23.1% | ||||||||
| 22 May 23 | Q1 Mar 2023 | 1 | 31 Dec 2023 | 200.47 | 28.29 | 22.63 | 11.3% | 0.00 | 2.38 | 31.9% | 7.8% | 31.9% | 11.5% | ||||||||
| 23 Feb 23 | Q4 Dec 2022 | 4 | 31 Dec 2022 | 151.96 | 15.35 | 17.16 | 11.3% | 1.80 | 1.80 | 14.2% | 4.5% | 5.0% | 9.2% | ||||||||
| 09 Nov 22 | Q3 Sep 2022 | 3 | 31 Dec 2022 | 177.07 | 21.39 | 16.35 | 9.2% | 0.00 | 1.72 | 2.6% | 3.0% | 0.2% | 3.6% | ||||||||
| 16 Aug 22 | Q2 Jun 2022 | 2 | 31 Dec 2022 | 181.74 | 21.47 | 16.31 | 9.0% | 0.50 | 1.72 | 2.3% | 16.9% | 19.6% | 6.0% | ||||||||
| 17 May 22 | Q1 Mar 2022 | 1 | 31 Dec 2022 | 185.94 | 26.65 | 20.29 | 10.9% | 0.00 | 2.19 | 27.8% | 11.7% | 29.1% | 15.2% | ||||||||
| 15 Feb 22 | Q4 Dec 2021 | 4 | 31 Dec 2021 | 145.44 | 17.13 | 15.72 | 10.8% | 1.80 | 1.67 | 15.4% | 8.5% | 7.3% | 3.0% | ||||||||
| 18 Nov 21 | Q3 Sep 2021 | 3 | 31 Dec 2021 | 171.84 | 22.48 | 16.96 | 9.9% | 0.00 | 1.80 | 10.6% | 28.5% | 10.2% | 20.1% | ||||||||
| 17 Aug 21 | Q2 Jun 2021 | 2 | 31 Dec 2021 | 155.44 | 20.20 | 15.39 | 9.9% | 0.50 | 2.18 | 6.6% | 8.4% | 12.6% | 4.5% | ||||||||
| 03 May 21 | Q1 Mar 2021 | 1 | 31 Dec 2021 | 166.45 | 23.18 | 17.61 | 10.6% | 0.00 | 2.49 | 24.1% | 4.9% | 8.8% | 29.9% | ||||||||
| 22 Feb 21 | Q4 Dec 2020 | 4 | 31 Dec 2020 | 134.09 | 20.47 | 16.19 | 12.1% | 6.00 | 2.29 | 0.2% | 2.7% | 14.6% | 34.6% | ||||||||
| 12 Nov 20 | Q3 Sep 2020 | 3 | 31 Dec 2020 | 133.77 | 18.57 | 14.13 | 10.6% | 0.00 | 2.03 | 6.7% | 6.4% | 4.1% | 4.9% | ||||||||
| 13 Aug 20 | Q2 Jun 2020 | 2 | 31 Dec 2020 | 143.33 | 19.39 | 14.73 | 10.3% | 0.50 | 2.15 | 9.7% | 1.5% | 8.6% | 5.8% | ||||||||
| 18 May 20 | Q1 Mar 2020 | 1 | 31 Dec 2020 | 158.71 | 17.73 | 13.56 | 8.5% | 0.00 | 1.98 | 15.2% | 5.5% | 12.7% | 6.2% | ||||||||
| 13 Feb 20 | Q4 Dec 2019 | 4 | 31 Dec 2019 | 137.75 | 13.94 | 12.03 | 8.7% | 5.00 | 1.76 | 3.6% | 19.1% | 19.0% | 16.3% | ||||||||
| 29 Nov 19 | Q3 Sep 2019 | 3 | 31 Dec 2019 | 142.85 | 19.77 | 14.86 | 10.4% | 0.00 | 2.20 | 1.8% | 13.5% | 6.8% | 20.9% | ||||||||
| 30 Aug 19 | Q2 Jun 2019 | 2 | 31 Dec 2019 | 145.47 | 18.32 | 13.92 | 9.6% | 1.00 | 2.07 | 3.3% | 17.3% | 3.8% | 34.6% | ||||||||
| 21 May 19 | Q1 Mar 2019 | 1 | 31 Dec 2019 | 150.39 | 18.79 | 14.46 | 9.6% | 0.00 | 2.19 | 30.1% | 12.8% | 0.7% | 34.2% | ||||||||
| 18 Feb 19 | Q4 Dec 2018 | 4 | 31 Dec 2018 | 115.63 | 17.66 | 14.37 | 12.4% | 4.00 | 2.17 | 8.1% | 3.0% | 16.9% | 21.1% | ||||||||
| 28 Nov 18 | Q3 Sep 2018 | 3 | 31 Dec 2018 | 125.84 | 15.84 | 12.29 | 9.8% | 0.00 | 1.86 | 1.5% | 9.1% | 18.8% | 7.7% | ||||||||
| 26 Nov 18 | Q2 Jun 2018 | 2 | 31 Dec 2018 | 123.99 | 12.91 | 10.34 | 8.3% | 1.50 | 1.59 | 7.0% | 5.9% | 4.1% | 7.1% | ||||||||
| 28 May 18 | Q1 Mar 2018 | 1 | 31 Dec 2018 | 133.26 | 13.26 | 10.78 | 8.1% | 0.00 | 3.82 | 18.7% | 8.1% | 9.2% | 12.7% | ||||||||
| 28 Feb 18 | Q4 Dec 2017 | 4 | 31 Dec 2017 | 112.25 | 12.82 | 11.87 | 10.6% | 6.00 | 4.22 | 2.7% | 51.6% | 4.1% | 19.6% | ||||||||
| 17 Nov 17 | Q3 Sep 2017 | 3 | 31 Dec 2017 | 115.38 | 14.21 | 11.40 | 9.9% | 0.00 | 3.99 | 1.4% | 43.7% | 18.1% | 79.9% | ||||||||
| 25 Aug 17 | Q2 Jun 2017 | 2 | 31 Dec 2017 | 117.05 | 12.64 | 9.65 | 8.2% | 2.50 | 3.46 | 5.1% | 47.9% | 0.9% | 114.4% | ||||||||
| 22 May 17 | Q1 Mar 2017 | 1 | 31 Dec 2017 | 123.31 | 12.12 | 9.56 | 7.8% | 0.00 | 3.43 | 66.6% | 55.2% | 3.6% | 21.9% | ||||||||
| 24 Feb 17 | Q4 Dec 2016 | 4 | 31 Dec 2016 | 74.03 | 6.30 | 9.93 | 13.4% | 0.04 | 3.41 | 7.8% | 17.2% | 56.5% | 35.3% | ||||||||
| 21 Nov 16 | Q3 Sep 2016 | 3 | 31 Dec 2016 | 80.30 | 7.52 | 6.34 | 7.9% | 0.00 | 2.23 | 1.5% | 1.2% | 40.8% | 26.5% | ||||||||
| 22 Aug 16 | Q2 Jun 2016 | 2 | 31 Dec 2016 | 79.14 | 7.72 | 4.50 | 5.7% | 2.50 | 1.41 | 0.4% | 40.5% | 42.6% | 23.0% | ||||||||
| 18 May 16 | Q1 Mar 2016 | 1 | 31 Dec 2016 | 79.47 | 9.94 | 7.84 | 9.9% | 0.00 | 2.81 | 11.1% | 74.3% | 48.9% | 12.6% | ||||||||
| 23 Feb 16 | Q4 Dec 2015 | 4 | 31 Dec 2015 | 89.40 | 17.53 | 15.34 | 17.1% | 5.50 | 9.19 | 12.6% | 75.2% | 77.8% | 37.9% | ||||||||
| 24 Nov 15 | Q3 Sep 2015 | 3 | 31 Dec 2015 | 79.37 | 11.62 | 8.62 | 10.9% | 0.00 | 5.17 | 41.0% | 77.1% | 47.5% | 0.7% | ||||||||
| 25 Aug 15 | Q2 Jun 2015 | 2 | 31 Dec 2015 | 56.31 | 8.41 | 5.85 | 10.4% | 4.00 | 4.19 | 23.5% | 38.6% | 34.8% | 22.2% | ||||||||
| 18 May 15 | Q1 Mar 2015 | 1 | 31 Dec 2015 | 45.60 | 12.20 | 8.97 | 19.7% | 0.00 | 6.43 | 10.6% | 12.6% | 19.3% | 7.2% | ||||||||
| 24 Feb 15 | 31/12/14 | 4 | 31/12/14 | 51.02 | 13.92 | 11.12 | 21.8% | 14.50 | 8.01 | 13.8% | 11.6% | 28.1% | 19.4% |
DPHARMA Historical Dividends
DPHARMA Financial Ratios
| EPS | 8.68 sen |
| Trailing PE (Sector Median: 16.1) | 15.2 |
| PEG | 0.27 |
| Altman Z | 1.6 |
| Beaver | 0.11 |
| Current Ratio | 2.54 |
| Debt-Equity (DE) Ratio | 0.95 |
| FCF Yield | 4.34 % |
| Revenue QoQ | 0.32 % |
| Revenue YoY | 6.59% |
| Profit QoQ | 11.72 % |
| Profit YoY | 44.73 % |
| Profit Margin (Sector Median: 5.0) | 9.27 % |
| ROE (ROIC: 7.63) | 11.22 % |
| Dividend Per Share (DPS) | 3.5 sen |
| Dividend Yield (DY) | 2.65 % |
DPHARMA Adjusted Financial Ratios
Ratios below have been recalculated after adjusting for One Off Gain/Loss detected from Quarterly reports
| EPS | |
| Trailing PE (Sector Median: 16.1) | |
| Profit QoQ | |
| Profit YoY | |
| Profit Margin (Sector Median: 5.0) | |
| ROE (ROIC: 8.26) | |
| Altman Z |
DPHARMA Fair Value
Weighted Average Fair Value:
| Discounted Cash Flow (DCF) 5% Growth | |
| Discounted Cash Flow (DCF) 10% Growth | |
| Relative Valuation | |
| Average Analysts FV based on 4 rating(s) |
| Graham Formula | |
| Graham Number | |
| Net Tangible Asset (NTA) | 0.77 | Consistent QR FV |
The Fair Value numbers are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The figures shown here should be taken as educational purposes only
Advanced Calculators
Calculate the fair value of the stock based on expected growth / risk, contract / award value, forecasted profit or forecasted revenue.
| Forward PE FV Calculator | |
| Latest Profit (adjusted) [M] | 19.25 |
| Expected Profit (Next QR) [M] | |
| Expected Profit (After QR above) [M] | |
| Expected Profit (After QR above) [M] | |
| Estimated Fair Value |
| Growth/Risk Fair Value Calculator | |
| Expected growth (%) | |
| Estimated downside / risk (%) | |
| Estimated New DCF Fair Value |
| Contract/Award Contribution Calculator | |
| Contract/Award Value (in Million) | |
| Estimated Contribution to Stock Price | |
| Estimated New DCF Fair Value |
| Profit-Based Calculator | |
| Expected Profit (M) | |
| for Year | |
| Estimated New DCF Fair Value |
| Revenue-Based Calculator | |
| Expected Revenue (M) | |
| for Year | |
| Estimated New DCF Fair Value |
| Market Pricing | |
| Expected Profit (M) | 461.63 |
| Expected Revenue (M) | 4254.63 |
| Expected Growth (%) | 31.0 |
The Fair Value calculated using this calculators are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The purpose of this tool is to help investor to quickly calculate their own expected Fair Value based on their own research
DPHARMA Directors Share Purchases (Beta)
No transaction in the last 2 months.
DPHARMA Summary
Market Cap: 1269 M.
Market Cap Class: Middlers
Number of Shares: 961 M.
Adjusted Float: 47.0%.
Stock highly correlated with
LHI (49%)
TAKAFUL (49%)
ORIENT (48%)
SCIENTX (48%)
Duopharma Biotech Berhad, formerly known as CCM Duopharma Biotech Berhad. Duopharma core competencies in the pharmaceutical industry include manufacturing, research and development, and commercialization and marketing of over 300 generic drugs, including Omesec and Prelica, as well as Consumer Healthcare (CHC) products such as CHAMPS, FLAVETTES, PROVITON, and Uphamol, which are well-known and accepted by consumers in Malaysia, the region, and around the world. With technological and commercialization agreements with trustworthy and powerful international partners, the Company has also ventured into the biosimilars space.Their headquarters is located in Kuala Lumpur, Malaysia.
Sectors: Consumer Products, Healthcare, Pharmaceuticals, Vaccine
Code: 7148
Website: http://duopharmabiotech.com/
Related Links: Bursa | Annual Report | Announcement
Warrant Info:
No warrants listed
DPHARMA Top Shareholdings
Updated on 31-Mar-2023
| Shareholder | % | Value (M) |
|---|---|---|
| Permodalan Nasional Berhad | 44.0% | 558.75 |
| Employees Provident Fund Board | 10.44% | 132.61 |
| Amanah Saham Bumiputera | 4.43% | 56.2 |
| Amanah Saham Malaysia | 2.31% | 29.33 |
| Tabung Haji | 1.92% | 24.38 |
| Billion Victory Sdn Bhd | 1.58% | 20.09 |
| National Trust Fund | 1.33% | 16.9 |
| Public Islamic Treasures Growth Fund | 1.06% | 13.45 |
| Manulife Investment Shariah Progress Fund | 0.91% | 11.55 |
| Prulink Equity Fund | 0.74% | 9.41 |
| Eastspring Investments Small-Cap Fund | 0.56% | 7.09 |
| Participating Fund | 0.55% | 7.0 |
| Prulink Strategic Fund | 0.49% | 6.25 |
| Manulife Investment Progress Fund | 0.38% | 4.83 |
| Manulife Investment Al Fauzan | 0.37% | 4.7 |
| Principal Dali Equity Growth Fund | 0.34% | 4.29 |
| Asean Growth Fund | 0.33% | 4.13 |
| Syarikat Takaful Malaysia Keluarga Berhad | 0.32% | 4.11 |
| Affin Hwang Wholesale Equity Fund | 0.28% | 3.54 |
| Hong Leong Assurance Berhad | 0.27% | 3.47 |
| Ooi Keng Tan | 0.27% | 3.44 |
| Kenanga Shariah Growth Opportunities Fund | 0.25% | 3.2 |
| Gibraltar BSN Aggressive Fund | 0.19% | 2.39 |
| Hong Leong Msig Takaful Berhad | 0.18% | 2.35 |
Frequently Asked Questions
Duopharma Biotech Berhad, formerly known as CCM Duopharma Biotech Berhad. Duopharma core competencies in the pharmaceutical industry include manufacturing, research and development, and commercialization and marketing of over 300 generic drugs, including Omesec and Prelica, as well as Consumer Healthcare (CHC) products such as CHAMPS, FLAVETTES, PROVITON, and Uphamol, which are well-known and accepted by consumers in Malaysia, the region, and around the world. With technological and commercialization agreements with trustworthy and powerful international partners, the Company has also ventured into the biosimilars space.Their headquarters is located in Kuala Lumpur, Malaysia. The company is listed on Bursa Malaysia and operates in the Consumer Products, Healthcare, Pharmaceuticals and Vaccine sectors.
Yes, DUOPHARMA BIOTECH BHD is listed as Shariah-compliant.
The latest share price of DUOPHARMA BIOTECH BHD is RM 1.32 updated on 23 January 2026 16:55.
As of now, DUOPHARMA BIOTECH BHD has a market capitalization of 1269M based on the latest financial data.
iSaham's technical analysis indicates that DUOPHARMA BIOTECH BHD's support level is at RM 1.26 and its resistance level is at RM 1.32, based on moving averages and price patterns.
The 52-week high for DUOPHARMA BIOTECH BHD is RM 1.34
DUOPHARMA BIOTECH BHD's share price has increased by 6.45% year-to-date, influenced by market trends and company performance.
DUOPHARMA BIOTECH BHD declared a dividend of 3.5 sen for the year 2025-11-13. View more details on DUOPHARMA BIOTECH BHD's Historical Dividends page.
The main shareholders of DUOPHARMA BIOTECH BHD include Permodalan Nasional Berhad, Employees Provident Fund Board and Amanah Saham Bumiputera. View more on DUOPHARMA BIOTECH BHD Top Shareholders page.
You can buy DUOPHARMA BIOTECH BHD shares through any licensed online broker or trading platform registered with Bursa Malaysia. If you're new to investing, iSaham can help you open an account with M+ Online, one of Malaysia's leading brokers.
When you open your M+ account through the iSaham team, you can get iSaham Pro for free as a bonus offer.
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.